FDA data Registry peer set 1 peer

Alternatives to rolapitant

1 same-class SPL records vs rolapitant - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.

Brand: Varubi

NK1 Receptor Antagonist (Antiemetic) Prescription 1 alternative found

About rolapitant

Varubi is a medicine that helps prevent nausea and vomiting caused by chemotherapy. It is used with other anti-nausea medicines.

Used for: Varubi is used to prevent delayed nausea and vomiting in adults. This nausea and vomiting is caused by cancer chemotherapy. It is used for both the first and repeat treatments of chemotherapy.

1 NK1 Receptor Antagonist (Antiemetic) peers (wide set)

Compare rolapitant vs aprepitant side-by-side →

rolapitant vs aprepitant · FAERS reaction fields

FAERS top-reaction field "Nausea" shows the widest count spread between rolapitant and aprepitant in this extract (2,066-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.

Side Effect rolapitant aprepitant
Death 141 -
Nausea 79 2,145
Fatigue 50 1,769
Infusion Related Reaction 40 972
Dyspnoea 34 1,508
Decreased Appetite 33 1,038
Flushing 32 -
Diarrhoea 29 1,542

"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.

rolapitant peer mix vs class inventory

Peer mix

0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for NK1 Receptor Antagonist (Antiemetic): 2 drugs.

Frequently Asked Questions

What same-class SPL records sit beside rolapitant?
This registry lists 1 NK1 Receptor Antagonist (Antiemetic) medication records beside rolapitant, including aprepitant. Grouping is therapeutic-class indexing from openFDA/SPL, not a product recommendation.

Reading a wide NK1 Receptor Antagonist (Antiemetic) peer set (1 records)

rolapitant (Varubi) sits in a wide NK1 Receptor Antagonist (Antiemetic) peer set (1 of 1 class peers shown). Labeled indication field for rolapitant: Varubi is used to prevent delayed nausea and vomiting in adults.

Top FAERS reaction fields for rolapitant total 489 reports across 10 reactions, set beside aprepitant. Counts are exposure-weighted submissions, not per-patient risk.

Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.

Full rolapitant profile →

Field note for rolapitant: see also the generic vs brand label guide when reading Varubi SPL strings.